Actelion

This study is testing the safety and correct dosing of a drug called selexipag in children with pulmonary arterial hypertension (PAH), a serious condition affecting blood vessels in the lungs. The goal is to find the right dose for children aged 2 to 18 years old, based on what w…

This study is testing whether adding a drug called selexipag to standard treatments can help slow down the progression of pulmonary arterial hypertension (PAH) in children aged 2 to 18. PAH is a rare, serious condition where blood pressure is too high in the lungs. The main goal …

This study is testing if a higher dose (75 mg) of the drug macitentan is better than the standard dose (10 mg) at delaying serious health problems or death in adults with pulmonary arterial hypertension (PAH), a rare and serious lung disease. About 935 participants will be random…